Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:51:48 EDT Sat 15 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:VKTX - VIKING THERAPEUTICS INC - https://www.vikingtherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VKTX - Q2.030.76·117.363.630.89+1.163.94,581.8139,06830,90930.125  31.48  29.7189.0997  24.407519:57:15Mar 1115 min RT 2¢

Recent Trades - Last 10 of 30909
Time ETExPriceChangeVolume
19:57:15Q31.04661.3166323
19:54:54Q31.04631.3163200
19:53:13Q30.951.2265
19:51:20Q31.001.2710
19:51:06Q31.001.27300
19:47:14Q31.001.2710
19:46:58Q30.931.20500
19:43:54Q30.951.223
19:42:23Q30.981.253
19:42:23Q30.951.227

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-11 07:03U:VKTXNews ReleaseViking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
2025-03-04 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2025-02-05 16:05U:VKTXNews ReleaseViking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
2025-01-29 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
2025-01-08 07:03U:VKTXNews ReleaseViking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
2025-01-06 16:05U:VKTXNews ReleaseViking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
2024-11-19 16:03U:VKTXNews ReleaseViking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(TM) 2024
2024-11-12 16:05U:VKTXNews ReleaseViking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(TM) 2024
2024-11-04 06:30U:VKTXNews ReleaseViking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek(TM) 2024
2024-10-31 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2024-10-28 16:05U:VKTXNews ReleaseViking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek(TM) 2024
2024-10-23 16:05U:VKTXNews ReleaseViking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2024-10-16 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024
2024-10-09 07:00U:VKTXNews ReleaseViking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
2024-08-28 16:03U:VKTXNews ReleaseViking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
2024-07-24 16:05U:VKTXNews ReleaseViking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
2024-07-17 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
2024-06-24 07:33U:VKTXNews ReleaseViking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
2024-06-04 07:05U:VKTXNews ReleaseViking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
2024-05-30 16:03U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences